Interim-20-ID-02

Committee: Infectious Disease

Title: Update to the standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19)

☒ Check this box if this position statement is an update to an existing standardized surveillance case definition and include the most recent position statement number here: Interim-20-ID-01

Synopsis: This position statement updates the standardized case definition for 2019 novel coronavirus disease (COVID-19), including asymptomatic infections caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), and retains COVID-19 as a nationally notifiable condition. Updates clarify clinical, laboratory, epidemiologic linkage, and vital records criteria for case ascertainment and case classification based on the continued evolution of the COVID-19 pandemic. Updates probable case classifications and adds suspect case classifications.

I. Statement of the Problem
Introduction of SARS-CoV-2, the virus that causes 2019 novel coronavirus disease (COVID-19), into the United States has resulted in the need for standardized surveillance to assist in understanding the transmission and epidemiology of the disease in U.S. jurisdictions. Public health agencies are investigating reported COVID-19-like illnesses and identifying infected people (cases) through laboratory testing. Nationwide standardized surveillance is necessary to provide consistent case identification and classification, measure the potential burden of illness, characterize the epidemiology of medically attended and moderate to severe COVID-19 in the United States, detect community transmission, and inform public health response to clusters of illness and efficacy of population-based non-pharmaceutical interventions on the epidemic.

II. Background and Justification
In late December 2019, investigation of a cluster of pneumonia cases of unknown origin in Wuhan, China resulted in identification of a novel coronavirus. The virus is distinct from both SARS-CoV and MERS-CoV, although closely related. Early epidemiologic findings indicate COVID-19 may be less severe than SARS or MERS, but evidence suggests that the virus is more contagious than its predecessors. SARS-CoV-2 is a newly identified pathogen and it is assumed there is no pre-existing human immunity to the virus. Initial seroconversion, including neutralizing antibodies, has been documented and there is some evidence that immunity to SARS-CoV-2 re-challenge during early convalescence is likely. The extent of long-term immunity from anamnestic responses is unknown currently. At the beginning of the pandemic, everyone was assumed to be susceptible; it is now known that there are risk factors that increase an individual’s illness severity.

Those at highest risk for severe disease and death include people aged over 60 years (especially those 85 years and older) and those with underlying conditions such as obesity, hypertension, diabetes, cardiovascular disease, chronic respiratory or kidney disease, immunosuppression from solid organ transplant, and sickle cell disease. Disease in children mostly appears to be relatively mild, and growing evidence that a significant proportion of infections across all age groups are asymptomatic.

Cases of COVID-19 in China and the initial U.S. cases in early March 2020 were clustered. Most cases in China occurred in households and in Washington, for example, a significant cluster was associated with a long-term care facility. By mid-March, multiple areas in the United States reported cases with no direct epidemiologic link to confirmed cases. As of July 2020, widespread community transmission of SARS-CoV-2 has been documented in geographically dispersed regions. Ongoing surveillance of illness, risk factors, and epidemiologic linkage is needed.
to characterize the disease transmission in the United States, to inform intervention and mitigation strategies, and to monitor and assess their impacts.

Epidemiological reports from the field are demonstrating a growing importance of presymptomatic and asymptomatic infections from two lines of evidence: the serial interval of COVID-19 appears to be close to or shorter than its median incubation period and clusters linked to presymptomatic and asymptomatic index cases.\(^2\)\(^3\) CSTE realizes that field investigations will involve evaluations of persons with no symptoms and these individuals will need to be counted as cases.

Because of the rapid advancement in the science of COVID-19 disease and SARS-CoV-2 infection, CSTE is updating this position statement within four months of its first interim approval by the Executive Board on April 5, 2020. In these four months, CSTE has received feedback from members on implementation, and in addition, antigen detection tests and serologic tests have been developed and authorized for use by the FDA. This update clarifies interpretation of antigen detection tests and serologic test results within the case classification. CSTE acknowledges the dual utility of these tests for public health surveillance of COVID-19 and clinical diagnosis of COVID-19. Classifying a test as confirmatory, presumptive, or supportive laboratory evidence is intended solely to assist a public health agency with case investigation and case counting, in the context of population health, that will lead to public health action. A provider may order a test under a variety of circumstances ranging from a drive-through testing site in a minimally symptomatic or asymptomatic person where very little clinical or epidemiologic data will be collected, to an acutely ill person presenting in an emergency department for hospital admission. The provider will use the testing platform that best fits the clinical situation, testing availability, and diagnostic capability, which should not be influenced by this CSTE position statement.

### III. Statement of the desired action(s) to be taken

CSTE recommends the following actions:

1. Implement a standardized surveillance case definition for COVID-19.
   
   - A. Utilize standard sources (e.g. reporting\(^*\)) for case ascertainment for COVID-19. Surveillance for COVID-19 should use the recommended sources of data to the extent of coverage presented in Section V.
   
   - B. Utilize standardized criteria for case ascertainment for COVID-19 presented in Section VI and Table VI in Technical Supplement.
   
   - C. Utilize standardized criteria for case classification for COVID-19 presented in Sections VII and Table VII in Technical Supplement.

2. Utilize standardized criteria for case ascertainment and classification (based on Sections VI and VII and Technical Supplement) for COVID-19 and retain COVID-19 to the Nationally Notifiable Condition List.
   
   - ☐ Immediately notifiable, extremely urgent (within 4 hours)
   - ☒ Immediately notifiable, urgent (within 24 hours)
   - ☐ Routinely notifiable
   - ☐ No longer notifiable

3. CSTE recommends that all States and Territories enact laws (statute or rule/regulation as appropriate) to make COVID-19 reportable in their jurisdiction. Jurisdictions (e.g. States and Territories) conducting surveillance (according to these methods) should submit case notifications\(^**\) to CDC.

4. Expectations for Message Mapping Guide (MMG) development for a newly notifiable condition: the National Notifiable Diseases Surveillance System (NNDSS) is transitioning to HL7-based messages for case notifications; the specifications for these messages are presented in MMGs. When CSTE recommends a new condition be made nationally notifiable, CDC must obtain Office of Management and Budget Paperwork Reduction Act (OMB PRA) approval prior to accepting case notifications for the new condition.

\(^2\)\(^3\)

Council of State and Territorial Epidemiologists
Interim-20-ID-02
condition. Under anticipated timelines, notification using the Generic V2 MMG would support transmission of the basic demographic and epidemiologic information common to all cases and could begin with the new MMWR year following the CSTE annual conference. Input from CDC programs and CSTE would prioritize development of a disease-specific MMG for the new condition among other conditions waiting for MMGs.

5. CDC should publish data on COVID-19 as appropriate (see Section IX).

CSTE recommends the following case statuses be included in the CDC Print Criteria:

- ☑ Confirmed
- ☑ Probable
- ☐ Suspect
- ☐ Unknown

6. CSTE recommends that all jurisdictions (e.g. States, Localities, or Territories) with legal authority to conduct public health surveillance follow the recommended methods outlined in this recommendation and in the accompanying standardized surveillance position statement.

*Reporting: process of a healthcare provider or other entity submitting a report (case information) of a condition under public health surveillance TO local, state, or territorial public health. Note: notification is addressed in a Nationally Notifiable Conditions Recommendation Statement and is the process of a local, state, or territorial public health authority submitting a report (case information) of a condition on the Nationally Notifiable Conditions List TO CDC.

**Notification: process of a local or state public health authority submitting a report (case information) of a condition on the Nationally Notifiable Conditions List TO CDC.

IV. Goals of Surveillance

Surveillance of COVID-19 is necessary to characterize the epidemiology of the disease in the United States, to measure the burden of disease in the United States health system, and to inform public health action.

V. Methods for Surveillance: Surveillance for COVID-19 should use the recommended sources of data and the extent of coverage listed in Table V.

<table>
<thead>
<tr>
<th>Source of data for case ascertainment</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Population-wide</td>
</tr>
<tr>
<td>Clinician reporting</td>
<td>X</td>
</tr>
<tr>
<td>Laboratory reporting</td>
<td>X</td>
</tr>
<tr>
<td>Reporting by other entities (e.g., hospitals, veterinarians, pharmacies, poison centers), specify: Hospitals</td>
<td>X</td>
</tr>
<tr>
<td>Death certificates</td>
<td>X</td>
</tr>
<tr>
<td>Hospital discharge or outpatient records</td>
<td>X</td>
</tr>
<tr>
<td>Data from electronic medical records</td>
<td>X</td>
</tr>
<tr>
<td>Telephone survey</td>
<td></td>
</tr>
<tr>
<td>School-based survey</td>
<td></td>
</tr>
<tr>
<td>Other, specify: diagnosis codes, autopsy reports</td>
<td>X</td>
</tr>
</tbody>
</table>

As commercial laboratories implement testing for SARS-CoV-2, laboratory reporting will be the most common source of data. Healthcare providers and facilities who diagnose or become aware of clinically compatible COVID-19 cases should report them to public health authorities.

VI. Criteria for case ascertainment

A. Narrative: A description of suggested criteria for case ascertainment of a specific condition.

Symptoms of COVID-19 are non-specific and the disease presentation can range from no symptoms (asymptomatic) to severe pneumonia, respiratory failure, and death. COVID-19 is a mild to moderate illness for approximately 80% of individuals evaluated with the disease; 15% have severe infection requiring supplemental
Council of State and Territorial Epidemiologists
Interim-20-ID-02

oxygen; and 5% of individuals have critical infections requiring mechanical ventilation.\(^4\) People with COVID-19 generally develop signs and symptoms, including mild respiratory symptoms and fever \(\sim\)5 days after infection (mean incubation period 5-6 days, range 1-14 days).\(^5\) In exposed populations such as nursing home residents, half of all infections detected during cohort screening may be presymptomatic or asymptomatic.\(^6\)

A1. Clinical Criteria for Reporting

In the absence of a more likely diagnosis, any medically attended person with:

- At least two of the following symptoms:
  - fever (measured or subjective),
  - chills,
  - rigors,
  - myalgia,
  - headache,
  - sore throat,
  - nausea or vomiting,
  - diarrhea,
  - fatigue,
  - congestion or runny nose

  OR

- Any one of the following symptoms:
  - cough,
  - shortness of breath,
  - difficulty breathing,
  - new olfactory disorder

  OR

- Severe respiratory illness with at least one of the following:
  - Clinical or radiographic evidence of pneumonia,
  - Acute respiratory distress syndrome (ARDS).

A2. Laboratory Criteria for Reporting

- Detection of SARS-CoV-2 RNA in a clinical specimen using a molecular amplification test.
- Detection of specific antigen in a clinical or autopsy specimen.
- Detection of specific antibody in serum, plasma, or whole blood.

A3. Epidemiologic Linkage Criteria for Reporting

In a person with clinically compatible symptoms with one or more of the following exposures in the 14 days before onset of symptoms:

- Close contact* with a confirmed or probable case of COVID-19 disease; OR
- Member of a risk cohort as defined by public health authorities during an outbreak.

*Close contact is generally defined as being within 6 feet for at least 15 minutes. However, it depends on the exposure level and setting; for example, in the setting of an aerosol-generating procedure in healthcare settings without proper personal protective equipment (PPE), this may be...
defined as any duration. Data are insufficient to precisely define the duration of exposure that constitutes prolonged exposure and thus a close contact.

A4. Vital Records Criteria for Reporting
A person whose death certificate lists COVID-19 disease or SARS-CoV-2 as an underlying cause of death or a significant condition contributing to death.

A5. Other Criteria for Reporting
Autopsy findings consistent with pneumonia or acute respiratory distress syndrome without an identifiable cause.

B. Disease-specific data elements to be included in the initial report

In addition to patient demographics, the following disease-specific data elements are expected to be included in all reports to public health agencies:

Laboratory Information:
- Specimen type
- Collection date
- Laboratory test performed
- Results

Clinical Information
- Description of clinical symptoms and signs of illness, or if asymptomatic
- Date of illness onset
- Hospitalization
- Underlying diseases or co-infections

Epidemiologic Information
- Known contact or linkage to COVID-19 cases
- Member of a risk cohort as defined by public health authorities during an outbreak

VII. Case Definition for Case Classification
This CSTE case definition is intended solely for public health surveillance purposes and does not recommend diagnostic criteria for clinical partners to utilize in diagnosing patients with potential COVID-19 disease or potential SARS-CoV-2 infection. See Section IX for information regarding which classifications of cases of COVID-19 should be publicly released by a public health department.

A. Narrative: Description of criteria to determine how a case should be classified.

A1. Clinical Criteria

In the absence of a more likely diagnosis:

- At least two of the following symptoms:
  - fever (measured or subjective),
  - chills,
  - rigors,
  - myalgia,
  - headache,
  - sore throat,
  - nausea or vomiting,
  - diarrhea,
  - fatigue,
  - congestion or runny nose

OR
● Any one of the following symptoms:
  o cough,
  o shortness of breath,
  o difficulty breathing,
  o new olfactory disorder,
  o new taste disorder

OR

● Severe respiratory illness with at least one of the following:
  o Clinical or radiographic evidence of pneumonia,
  o Acute respiratory distress syndrome (ARDS).

A2. Laboratory Criteria

Laboratory evidence using a method approved or authorized by the FDA7 or designated authority:

**Confirmatory** laboratory evidence:
  ● Detection of SARS-CoV-2 RNA in a clinical or autopsy specimen using a molecular amplification test

**Presumptive** laboratory evidence:
  ● Detection of SARS-CoV-2 by antigen test in a respiratory specimen

**Supportive** laboratory evidence:
  ● Detection of specific antibody in serum, plasma, or whole blood
  ● Detection of specific antigen by immunocytochemistry in an autopsy specimen

**The terms confirmatory, presumptive, and supportive are categorical labels used here to standardize case classifications for public health surveillance. The terms should not be used to interpret the utility or validity of any laboratory test methodology.**

A3. Epidemiologic Linkage

One or more of the following exposures in the prior 14 days:
  ● Close contact* with a confirmed or probable case of COVID-19 disease;
  ● Member of a risk cohort as defined by public health authorities during an outbreak.

*Close contact is generally defined as being within 6 feet for at least 15 minutes. However, it depends on the exposure level and setting; for example, in the setting of an aerosol-generating procedure in healthcare settings without proper PPE, this may be defined as any duration. Data are insufficient to precisely define the duration of exposure that constitutes prolonged exposure and thus a close contact.

A4. Vital Records Criteria

A death certificate that lists COVID-19 disease or SARS-CoV-2 as an underlying cause of death or a significant condition contributing to death.

A5. Case Classifications

**Confirmed:**
  ● Meets confirmatory laboratory evidence.
Probable:
- Meets clinical criteria AND epidemiologic linkage with no confirmatory lab testing performed for SARS-CoV-2.
- Meets presumptive laboratory evidence.
- Meets vital records criteria with no confirmatory laboratory evidence for SARS-CoV-2.

Suspect:
- Meets supportive laboratory evidence*** with no prior history of being a confirmed or probable case.

*** For suspect cases (positive serology only), jurisdictions may opt to place them in a registry for other epidemiological analyses or investigate to determine probable or confirmed status.

B. Criteria to distinguish a new case of this disease or condition from reports or notifications which should not be enumerated as a new case for surveillance

A repeat positive test for SARS-CoV-2 RNA using a molecular amplification detection test within 3 months of the initial report should not be enumerated as a new case for surveillance purposes. To date, there has been minimal evidence of re-infection among persons with a prior confirmed COVID-19 infection and growing evidence that repeat positive RNA tests do not correlate with active infection when viral culture is performed. Similarly the experience with other coronaviruses is that reinfection is rare within the first year.\(^8,9\) NOTE: The time period of 3 months will be extended further when more data becomes available to show risk of reinfection remains low within one year of the initial report.

VIII. Period of Surveillance

Ongoing

IX. Data sharing/release and print criteria

CSTE recommends the following case statuses* be included in the ‘case’ count released outside of the public health agency:

- Confirmed
- Probable
- Suspect
- Unknown

* Which case statuses are included in the case counts constitute the “print criteria.”

Jurisdictions (e.g., States and Territories) conducting surveillance under this case definition can voluntarily submit de-identified case information to CDC, if requested and in a mutually agreed upon format.

Production of national data summaries and national data re-release for non-NNCs:
- Prior to release of national data summaries CDC should follow the CDC/ATSDR Policy on Releasing & Sharing Data, issued on April 16, 2003 and referenced in 11-SI-01 and custodians of such data should consult the CDC-CSTE Intergovernmental Data Release Guidelines Working Group report (www.cste2.org/webpdfs/drgwgreport.pdf) which contains data release guidelines and procedures for CDC programs re-releasing state, local, or territorial-provided data.
- CDC programs have a responsibility, in collaboration with states, localities, and territories, to ensure that CDC program-specific data re-release procedures meet the needs of those responsible for protecting data in the states and territories.
- In accordance with CSTE Position Statement 11-SI-04, CDC should apply the Revised Guidelines for Determining Residency for analyses and counting cases.

---

\(^8\)

\(^9\)
## X. Revision History

<table>
<thead>
<tr>
<th>Position Statement</th>
<th>Section of Document</th>
<th>Revision Description</th>
</tr>
</thead>
</table>
| Interim-20-ID-01   | II. Background and Justification | • Updated background related to immunity, risk factors, and pandemic characteristics.  
• Added rationale for updating case definition within four months of publication of Interim-20-ID-01.  
• Added explanation on interpretation of position statement and case classification criteria. |
| Interim-20-ID-01   | VI. Criteria for case ascertainment | A. Narrative: Added clinical symptoms context to narrative.  
A1. Clinical Criteria for Reporting:  
• Adjusted formatting for clarity.  
• Clarified that person must be medically attended without specifying type of medical visit.  
• Added the following to “at least two” symptoms: nausea or vomiting, diarrhea, fatigue, and congestion or runny nose.  
• Moved the following from “at least two” symptoms to “any one” symptom: new olfactory disorder, new taste disorder.  
A2. Laboratory Criteria for Reporting:  
• Removed duplicative “detection” from “detection of […] using a molecular amplification detection test.”  
• Added autopsy specimen as an appropriate specimen type for detection of specific antigen.  
• Removed “indicative of a new or recent infection” from detection of specific antibody in serum, plasma, or whole blood, and removed related serologic testing footnote.  
A3. Epidemiologic Linkage Criteria for Reporting:  
• Removed criteria: Travel to or residence in an area with sustained, ongoing community transmission of SARS-CoV-2.  
• Revised close contact epi linkage criterion from “Close contact with a person diagnosed with COVID-19” to “Close contact with a confirmed or probable case of COVID-19 disease.”  
• Updated close contact definition:  
  o Adjusted timeframe for close contact from 10-30 minutes to 15 minutes.  
  o Clarified that close contact definition is dependent on the exposure level and setting, and added one extreme example within the healthcare setting.  
A4. Vital Records Criteria for Reporting:  
• Clarified COVID-19 disease or SARS-CoV-2 must be “an underlying cause of death” or a significant condition contributing to death on a death certificate to trigger reporting to public health. |
| Interim-20-ID-01   | VI. Criteria for case ascertainment | B. Disease-specific data elements to be included in the initial report:  
• Removed: Recent travel to or residence in an area with sustained, ongoing community transmission of SARS-CoV-2. |
| Interim-20-ID-01   | VII. Case Definition for Case Classification | Clarified purpose of case definition. |
| Interim-20-ID-01   | VII. Case Definition for Case Classification | A1. Clinical Criteria:  
• Adjusted formatting for clarity.  
• Added the following to “at least two” symptoms: nausea or vomiting, diarrhea, fatigue, and congestion or runny nose.  
• Moved the following from “at least two” symptoms to “any one” symptom: new olfactory disorder, new taste disorder |
A2. Laboratory Criteria:
- Added footnote explaining categorical labels used within case classification.
- Added reference to FDA website for most up-to-date list of authorized laboratory tests.
- Added autopsy specimen as an appropriate specimen type for molecular amplification detection tests to confirmatory laboratory evidence.
- Removed duplicative “detection” from “detection of […] using a molecular amplification detection test.”
- Clarified antigen detection evidence and limited appropriate specimen types to respiratory specimen for presumptive laboratory evidence.
- Recategorized antibody detection evidence in serum, plasma, or whole blood as supportive laboratory evidence and removed “indicative of a new or recent infection” and related serologic testing footnote.
- Added antigen detection by immunocytochemistry in an autopsy specimen as supportive laboratory evidence.

A3. Epidemiologic Linkage:
- Removed “before onset of symptoms” from epi linkage.
- Clarified epi linkage timing to linkage within prior 14 days.
- Removed duplicative epi linkage exposure, which equated to a probable case and is included in a separate epi linkage exposure criterion.
- Removed criteria: Travel to or residence in an area with sustained, ongoing community transmission of SARS-CoV-2.
- Updated close contact definition:
  - Adjusted timeframe for close contact from 10-30 minutes to 15 minutes.
  - Clarified that close contact definition is dependent on the exposure level and setting, and added one extreme example within the healthcare setting.

A4. Vital Records Criteria:
- Clarified COVID-19 disease or SARS-CoV-2 must be “an underlying cause of death” or a significant condition contributing to death on a death certificate to be considered for case classification.

A5. Case Classifications:
- Probable:
  - Removed the need for either clinical criteria or epidemiologic linkage to be paired with presumptive laboratory evidence.
  - Clarified a lack of confirmatory lab evidence paired with vital records criteria.
  - Clarified lab testing would be performed for SARS-CoV-2 and not COVID-19 disease.
- Suspect:
  - Added suspect case classification and related footnote.

<table>
<thead>
<tr>
<th>Interim-20-ID-01</th>
<th>VII. Case Definition for Case Classification</th>
<th>B. Criteria to distinguish a new case of this disease or conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>• Added criteria to distinguish a new case of COVID-19 using molecular amplification detection test.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interim-20-ID-01</th>
<th>XI. References</th>
<th>Removed irrelevant resources and added new, relevant resources.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interim-20-ID-01</td>
<td>NNC Recommendation Statement</td>
<td>Recommends COVID-19 be retained on the NNC List.</td>
</tr>
</tbody>
</table>
XII. References


XII. Coordination

Subject Matter Expert (SME) Consultants:

(1) Judith C Lovchik, PhD D(ABMM) Assistant Commissioner Public Health Protection and Laboratory Services Indiana State Department of Health 317-921-5808 jlovcik@isdh.in.gov

(2) Kirsten St. George, MAppSc, PhD Chief, Viral Diseases Wadsworth Center New York State Department of Health 518-474 4177 Kirsten.St.George@health.ny.gov

(3) Susan I. Gerber, MD Chief, Respiratory Viruses Branch Division of Viral Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention 404-639-3002 bhx1@cdc.gov

(4) Aron J. Hall, DVM, MSPH, Dipl ACVPM Division of Viral Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention 404-639-1869 ajhall@cdc.gov

(5) Sandra W. Roush, MT, MPH Surveillance Officer National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention 404-639-8741 sroush@cdc.gov

(6) Tom Shimabukuro, MD, MPH, MBA Immunization Safety Office Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious Diseases Centers for Disease Control and Prevention 404-498-0679 TShimabukuro@cdc.gov
(7) Katie Fullerton, MPH  
Associate Director for Surveillance  
Surveillance, Information Management, and Statistics Office  
Division of Foodborne, Waterborne, and Environmental Diseases  
National Center for Emerging and Zoonotic Infectious Diseases  
Centers for Disease Control and Prevention  
404-718-4714  
kfullerton@cdc.gov

(8) Adam J. Langer, DVM, MPH, DACVPM  
Chief, Surveillance, Epidemiology, and Outbreak Investigations Branch  
Division of Tuberculosis Elimination  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention  
404-639-8120  
ALanger@cdc.gov

Agencies for Response

(1) Centers for Disease Control and Prevention  
Robert R. Redfield, MD  
Director  
1600 Clifton Road NE  
Atlanta, GA 30329  
(404) 639-7000  
olx1@cdc.gov  
CC: John Howard, MD, MPH, JD, LLM, MBA  
Director of National Institute for Occupational Safety and Health  
202-245-0625, z kz1@cdc.gov

Agencies for Information:

(1) Food and Drug Administration  
Stephen Hahn  
Commissioner  
10903 New Hampshire Ave, Mail Stop HF-1  
Silver Springs, MD 20993-0002  
1-888-463-6332  
Stephen.Hahn@fda.hhs.gov

XIII. Author Information

Submitting and Presenting Author:

(1) Kathryn Turner, PhD MPH  
Deputy State Epidemiologist  
Idaho Division of Public Health  
Idaho Department of Health and Welfare  
450 West State Street, 4th Floor  
Boise, ID 83702  
208-334-5939  
Kathryn.Turner@dhw.idaho.gov
Co-Author(s):

(1)  ☒ Active Member
Sherri L. Davidson, Ph.D., M.P.H.
Interim State Epidemiologist
Epidemiology, Surveillance, & Informatics,
Infectious Diseases & Outbreaks Division
Alabama Department of Public Health
201 Monroe St, Suite 1464
Montgomery, AL 36104334-206-2050
sherri.davidson@adph.state.al.us

(2)  ☒ Active Member
Jim Collins MPH, RS
Director, Communicable Disease Division
Michigan Department of Health and
Human Services333 S. Grand Ave.
Lansing, MI 48909
517-284-4911
CollinsJ12@michigan.gov

(3)  ☒ Active Member
Sarah Y. Park, MD, FAAP
State Epidemiologist
Chief, Disease Outbreak Control Division
Hawaii Department of Health
1250 Punchbowl Street, Rm 443
Honolulu, HI 96813
808-587-6845
sarah.park@doh.hawaii.gov

(4)  ☒ Active Member
Caitlin S. Pedati MD, MPH, FAAP
Medical Director & State Epidemiologist
Iowa Department of Public Health
321 E. 12th Street
Lucas State Office Bldg.
Des Moines, IA 50319
515-281-3826
caitlin.pedati@idph.iowa.gov

(5)  ☒ Active Member
Ruth Lynfield, MD
State Epidemiologist and Medical Director
Minnesota Department of Health
625 Robert Street North, PO Box 64975
St. Paul, Minnesota 55164
651-201-5422
ruth.lynfield@state.mn.us

(6)  ☒ Active Member
Marcelle Layton, MD
Assistant Commissioner
Bureau of Communicable Disease
New York City Department of Health and
Mental Hygiene
42-09 28th Street CN22A
Long Island City, New York 11101
347-396-2656
mlayton@health.nyc.gov

(7)  ☒ Active Member
Sharon M. Watkins, PhD
Director, Bureau of Epidemiology
State Epidemiologist
Pennsylvania Department of Health
Room 933, Health and Welfare Building
625 Forster Street
Harrisburg PA 17120-0701
717-787-3350
Shawatkins@pa.gov
**Technical Supplement**

### Table VI. Table of criteria to determine whether a case should be reported to public health authorities.

<table>
<thead>
<tr>
<th>Criterion</th>
<th>COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Criteria for Reporting</strong></td>
<td></td>
</tr>
<tr>
<td>Patient medically attended</td>
<td>N  N</td>
</tr>
<tr>
<td>At least two of the following symptoms:</td>
<td>O  O</td>
</tr>
<tr>
<td>• Fever (measured or subjective)</td>
<td></td>
</tr>
<tr>
<td>• Chills</td>
<td></td>
</tr>
<tr>
<td>• Rigors</td>
<td></td>
</tr>
<tr>
<td>• Myalgia</td>
<td></td>
</tr>
<tr>
<td>• Headache</td>
<td></td>
</tr>
<tr>
<td>• Sore throat</td>
<td></td>
</tr>
<tr>
<td>• Nausea or vomiting</td>
<td></td>
</tr>
<tr>
<td>• Diarrhea</td>
<td></td>
</tr>
<tr>
<td>• Fatigue</td>
<td></td>
</tr>
<tr>
<td>• Congestion or runny nose</td>
<td></td>
</tr>
<tr>
<td>Any one of the following symptoms:</td>
<td>O  O</td>
</tr>
<tr>
<td>• Cough</td>
<td></td>
</tr>
<tr>
<td>• Shortness of breath</td>
<td></td>
</tr>
<tr>
<td>• Difficulty breathing</td>
<td></td>
</tr>
<tr>
<td>• New olfactory disorder</td>
<td></td>
</tr>
<tr>
<td>• New taste disorder</td>
<td></td>
</tr>
<tr>
<td>Clinical or radiographic evidence of pneumonia</td>
<td>O  O</td>
</tr>
<tr>
<td>Acute respiratory distress syndrome (ARDS)</td>
<td>O  O</td>
</tr>
<tr>
<td>No alternative more likely diagnosis</td>
<td>N  N</td>
</tr>
<tr>
<td><strong>Laboratory Criteria for Reporting</strong></td>
<td></td>
</tr>
<tr>
<td>Detection of SARS-CoV-2 RNA in a clinical specimen using a molecular amplification test</td>
<td>S</td>
</tr>
<tr>
<td>Detection of specific antigen in a clinical or autopsy specimen</td>
<td>S</td>
</tr>
<tr>
<td>Detection of specific antibody in serum, plasma, or whole blood</td>
<td>S</td>
</tr>
<tr>
<td><strong>Epidemiological Linkage Criteria for Reporting</strong></td>
<td></td>
</tr>
<tr>
<td>Close contact* in the 14 days before onset of symptoms with a confirmed or probable case of COVID-19 disease</td>
<td>O‡</td>
</tr>
<tr>
<td>Member of a risk cohort, as defined by public health authorities during an outbreak, in the 14 days before onset of symptoms</td>
<td>O‡</td>
</tr>
<tr>
<td><strong>Vital Records Criteria for Reporting</strong></td>
<td></td>
</tr>
<tr>
<td>A person whose death certificate lists COVID-19 disease or SARS-CoV-2 as an underlying cause of death or a significant condition contributing to death</td>
<td>S</td>
</tr>
<tr>
<td><strong>Other Criteria for Reporting</strong></td>
<td></td>
</tr>
<tr>
<td>Autopsy findings consistent with pneumonia or acute respiratory distress syndrome without an identifiable cause</td>
<td>S</td>
</tr>
</tbody>
</table>

**Notes:**

- **S** = This criterion alone is **SUFFICIENT** to report a case.
- **N** = All "N" criteria in the same column are **NECESSARY** to report a case.
- **O** = At least one of these "O" (ONE OR MORE) criteria in each category (categories=clinical evidence, laboratory evidence, and epidemiological evidence) **in the same column**—in conjunction with all "N" criteria in the same column—is required to report a case.

*Close contact is generally defined as being within 6 feet for at least 15 minutes. However, it depends on the exposure level and setting; for example, in the setting of an aerosol-generating procedure in healthcare settings without proper personal protective equipment (PPE), this may be defined as any duration. Data are insufficient to precisely define the duration of exposure that constitutes prolonged exposure and thus a close contact.*

*Epidemiologic linkage criteria are considered with clinical evidence, but are not sufficient, in the absence of symptoms, to report to public health.*

Council of State and Territorial Epidemiologists  
Technical Supplement: Interim-20-ID-02
Table VII. Classification Table: Criteria for defining a case of COVID-19.

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Confirmed</th>
<th>Probable</th>
<th>Suspect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Evidence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At least two of the following symptoms:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Fever (measured or subjective)</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Chills</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Rigors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Myalgia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Headache</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Sore throat</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Nausea or vomiting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Diarrhea</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Fatigue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Congestion or runny nose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difficulty breathing</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New olfactory disorder</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New taste disorder</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical or radiographic evidence of pneumonia</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute respiratory distress syndrome (ARDS)</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No alternative more likely diagnosis</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Laboratory Evidence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detection of SARS-CoV-2 RNA in a clinical or autopsy specimen using a</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>molecular amplification test**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detection of SARS-CoV-2 by antigen test** in a respiratory specimen</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detection of specific antibody*** in serum, plasma, or whole blood**</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detection of specific antigen by immunocytochemistry** in an autopsy</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>specimen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absence of molecular amplification detection test for SARS-CoV-2 RNA</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td><strong>Epidemiologic Linkage Evidence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Close contact* with a confirmed or probable case of COVID-19 disease in</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>the 14 days before onset of symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Member of a risk cohort, as defined by public health authorities during</td>
<td>O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>an outbreak, in the 14 days prior to onset of symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vital Records Evidence</strong></td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A death certificate that lists COVID-19 disease or SARS-CoV-2 as an</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>underlying cause of death or a significant condition contributing to</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>death</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Evidence</strong></td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No prior history of being a confirmed or probable case</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Criteria to distinguish a new case:</strong></td>
<td>N</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Positive SARS-CoV-2 RNA molecular amplification detection test** with</td>
<td>N</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>specimen collection more than 3 months after initial report</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:

S = This criterion alone is SUFFICIENT to classify a case.

N = All “N” criteria in the same column are NECESSARY to classify a case. A number following an “N” indicates that this criterion is only required for a specific disease/condition subtype (see below). If the absence of a criterion (i.e., criterion NOT present) is required for the case to meet the classification criteria, list the absence of criterion as a necessary component.

O = At least one of these “O” (ONE OR MORE) criteria in each category (categories=clinical evidence, laboratory evidence, and epidemiologic evidence) in the same column—in conjunction with all “N” criteria in the same column—is required to classify a case. A number following an “O” indicates that this criterion is only required for a specific disease/condition subtype.

*Close contact is generally defined as being within 6 feet for at least 15 minutes. However, it depends on the exposure level and setting; for example, in the setting of an aerosol-generating procedure in healthcare settings without proper PPE, this may be defined as any duration. Data are insufficient to precisely define the duration of exposure that constitutes prolonged exposure and thus a close contact.

**Test must be approved or authorized by the FDA or designated authority.

***For suspect cases (positive serology only), jurisdictions may opt to place them in a registry for other epidemiological analyses or investigate to determine probable or confirmed status.
Appendix 1
Epidemiological Classification of Work-Relatedness

The Epidemiological Classification of Work-Relatedness Appendix is a product of the CSTE Occupational Health Subcommittee. Please direct any questions or comments about the appendix to the Subcommittee co-chairs: Ken Rosenman (MI): rosenman@msu.edu and Sara Wuellner (WA): wues235@lni.wa.gov.

Background:
The CSTE Occupational Health Subcommittee created a workgroup to develop standardized surveillance guidance to improve exposure-associated classifications of confirmed or probable COVID-19 cases. This workgroup, representing state and federal occupational health specialists, had weekly conference calls with the goal of supporting identification of work-related COVID-19 transmission to better identify and control workplace clusters, provide critical information about patterns of disease among workers, better understand COVID-19 health disparities, and inform prevention and intervention efforts.

This guidance applies to cases that are classified as confirmed or probable according to the CSTE surveillance case definition for COVID-19.

The classification for work-related cases of COVID-19 may evolve as the epidemiology of and risk factors for SARS-CoV-2 are better understood. How sensitive or specific to make the work-related classification was considered. A more sensitive case-definition is more inclusive and allows employers to implement workplace intervention and prevention strategies, which are more likely to be successful than interventions outside the workplace, for example to address crowded housing. A second concern was that information on non-work contacts may be unknown and to require the exclusion of non-work contacts for a case to be classified as likely work-related may be overly specific and exclude work-related cases. For example, given a cluster of cases in a meat packing facility, it would be reasonable to call these cases likely work-related although for any given individual in that cluster an exposure outside of work may have been the actual source of infection.

This classification has been developed for population-based epidemiological purposes and is not intended for use to determine an individual’s eligibility for workers’ compensation or to assist employers with Occupation Safety and Health Administration (OSHA) record keeping requirements.

Definitions:
“Case” refers to a confirmed or probable case of COVID-19 (see accompanying position statement, Section VII.)

“Work-related” means a case was infected with SARS-CoV-2 from an exposure at work.

Exposure outside of the workplace within 14 days of onset of symptoms or test result that meets confirmatory or presumptive laboratory criteria:
- Contact outside of work with a person that meets the definition of a confirmed or probable case.
- Participation in an event determined to be associated with a COVID-19 cluster (i.e. celebration, funeral)
- Travel on a cruise ship or airplane determined to be associated with a COVID-19 cluster

Face-to-Face Work with Public
This category includes all paid and unpaid workers who have face-to-face contact with the public (i.e. excludes persons who have contact with public only by phone or computer). It also excludes health care workers, who are defined in a separate section.

The US Department of Labor Occupational Information Network (O*NET) database (https://www.onetonline.org) was used to identify occupations with face-to-face public contact. We used O*NET survey measures regarding how important it is to work directly with the public or with customers and how closely people work to others in each occupation. We manually reviewed the list of occupations and selected occupations where face-to-face contact with public was expected. An additional O*NET measure on how physically close to other people one works in each occupation was also considered.
Appendix 1: Epidemiological Classification of Work-Relatedness, created June 22, 2020

A joint CDC/CSTE committee has developed a definition of an outbreak as part of the document title, “Proposed Investigation Criteria and Outbreak Definition for COVID-19 in Non-Residential, Non-Healthcare Workplace Settings. July 14, 2020,” an excerpt from which is below. For the most up-to-date outbreak definition, please reference that document.

**Outbreak definition:**
Two or more laboratory-confirmed COVID-19 cases among workers at a facility with onset within a 14-day period, who are epidemiologically linked, do not share a household, and are not a close contact of each other outside of the workplace.

Work-Related Classification:
Work-related classifications are presented in three formats: 1) AND/OR logic statements, 2) a table, 3) and a flow diagram.

**Work-Related Classification in AND/OR Logic Statement Format**

**Likely Work-Related:**
- Worked outside the home for any amount of time in the 14 days prior to onset of illness or date of specimen collection **AND**
- Is a health care worker or work includes face-to-face contact with the public **AND**
- Is part of a cluster of COVID-19 illnesses among workers in a facility or has had contact with a co-worker, patient, resident, client, or customer classified as a confirmed or probable case. **OR**

---

1 Health departments may consider a higher threshold for defining an outbreak if there is a high case rate in the community (community transmission).

2 Detection of SARS-CoV-2 RNA or antigen in a clinical specimen using molecular amplification test.

3 For onset, use symptom onset date whenever available. If symptom onset date is unknown or if a case is asymptomatic, use specimen collection date for the first specimen that tested positive. The 14-day period refers to the 14 days before the date of first symptom onset or first positive test sample.

4 Health departments should verify to the best extent possible that cases were present in the same setting during the same time period (e.g., same shift/department, same physical work area); that the timing fits with likely timing of exposure; and that there is no other more likely source of exposure for identified cases (e.g., household or close contact to a confirmed case outside of workplace setting).

5 Close contact is defined as being within 6 feet for at least 15 minutes. However, it depends on the exposure level and setting; for example, in the setting of an aerosol-generating procedure in healthcare settings without proper personal protective equipment (PPE), this may be defined as any duration. Data are insufficient to precisely define the duration of exposure that constitutes prolonged exposure and thus a close contact. For updated definition of a close contact please refer to CDC Contact Tracing Plan Appendices website at https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/appendix.html#contact
- Worked outside the home for any amount of time in the 14 days prior to onset of illness or date of specimen collection **AND**
- Is a health care worker or work includes face-to-face contact with the public **AND**
- Has had no known contact with a confirmed or probable case outside the workplace.

**OR**

- Worked outside the home for any amount of time in the 14 days prior to onset of illness or date of specimen collection **AND**
- Is a non-health care worker and work does not include face-to-face contact with the public **AND**
- Is part of a cluster of COVID-19 illnesses among workers in a facility or has had contact with a co-worker classified as a confirmed or probable case.

**Possibly Work-Related:**

- Worked outside the home for any amount of time in the 14 days prior to onset of illness or date of specimen collection **AND**
- Is a health care worker or work includes face-to-face contact with the public **AND**
- Is not part of a cluster of COVID-19 illnesses among workers in a facility and has had no contact with a co-worker, patient, resident, client, or customer classified as a confirmed or probable case **AND**
- Has had contact with a confirmed or probable case outside the workplace.

**OR**

- Worked outside the home for any amount of time in the 14 days prior to onset of illness or date of specimen collection **AND**
- Is a non-health care worker and work does not include face-to-face contact with the public **AND**
- Is not part of a cluster of COVID-19 illnesses among workers in a facility **AND**
- Has had no contact with a co-worker classified as a confirmed or probable case.

**Not Work-Related:**

- A patient or resident in congregate care setting or a person incarcerated\(^6\) in the 14 days prior to onset of illness or date of specimen collection.

**OR**

- Did not work outside the home for any amount of time in the 14 days prior to onset of illness or date of specimen collection.

**Unable to Classify:**

- Not a patient or resident in congregate care setting or an incarcerated\(^6\) person in the 14 days prior to onset of illness or specimen collection date **AND**
- Unknown if worked outside the home for any amount of time in the 14 days prior to onset of illness or specimen collection date.

---

\(^6\) It is possible for a person who is incarcerated and in a work-release program to be exposed to a confirmed or probable case of COVID-19 at their assigned work site, and after case investigation, may be considered likely or possibly work-related.
<table>
<thead>
<tr>
<th>Work-Relatedness Classification</th>
<th>Health Care Worker who worked outside the home for any amount of time in the 14 days prior to onset of illness or specimen collection date</th>
<th>Worker with face-to-face public contact who worked outside the home for any amount of time in the 14 days prior to onset of illness or specimen collection date</th>
<th>All Other Workers who worked outside the home for any amount of time in the 14 days prior to onset of illness or specimen collection date</th>
<th>Not working outside the home in 14 days prior to onset of illness or date of specimen collection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Likely Work-Related</td>
<td>Is part of a cluster of COVID-19 illnesses among workers in a facility OR Has had contact with a co-worker, patient, or resident classified as a confirmed or probable case OR Has had no known contact with a confirmed or probable case outside the workplace.</td>
<td>Is part of a cluster of COVID-19 illnesses among workers in a facility OR Has had contact with co-worker, client, or customer classified as a confirmed or probable case OR Has had no known contact with a confirmed or probable case outside the workplace.</td>
<td>Is part of a cluster of COVID-19 illnesses among workers in a facility OR Has had close contact with a co-worker classified as a confirmed or probable case.</td>
<td>N/A</td>
</tr>
<tr>
<td>Possibly Work-Related</td>
<td>Not part of a cluster of COVID-19 illnesses among workers in a facility AND Has had no contact with a co-worker, patient, or resident classified as a confirmed or probable case AND Has had contact with a confirmed or probable case outside the workplace.</td>
<td>Not part of a cluster of COVID-19 illnesses among workers in a facility AND Has had no contact with a co-worker, client, or customer classified as a confirmed or probable case AND Has had contact with a confirmed or probable case outside the workplace.</td>
<td>Not part of a cluster of COVID-19 illnesses among workers in a facility AND Has had close contact with a co-worker classified as a confirmed or probable case.</td>
<td>N/A</td>
</tr>
<tr>
<td>Not Work-Related</td>
<td>No work outside the home in the 14 days prior to onset of illness or date of specimen collection OR A patient or resident in congregate care setting or a person incarcerated in the 14 days prior to onset of illness or date of specimen collection.</td>
<td>No work outside the home in the 14 days prior to onset of illness (or date of specimen collection OR A patient or resident in congregate care setting or a person incarcerated in the 14 days prior to onset of illness or date of specimen collection.</td>
<td>No work outside the home in the 14 days prior to onset of illness or date of specimen collection OR A patient or resident in congregate care setting or a person incarcerated in the 14 days prior to onset of illness or date of specimen collection.</td>
<td>No work outside the home in the 14 days prior to onset of illness or date of specimen collection.</td>
</tr>
</tbody>
</table>
Use of Data on Death Certificates to Determine Possible Work Relatedness:

Death certificates contain the usual occupation and industry of the deceased. They are readily available in all jurisdictions and the occupation and industry information on the death certificate may be used to determine work-relatedness of COVID-19 deaths. However, the work-related classification states that when it is unknown whether a person worked outside the home in the 14 days prior to the onset of illness or date of specimen collection a case is “not able to be classified.”

Death certificates could be matched to cases to obtain information about recent work outside the home and the occurrence of a work-related cluster. In the absence of this matching, working-aged individuals (18-70 years of age) with a death certificate that meets the vital records criteria in the accompanying position statement whose occupation or industry is 1) health care, 2) requires face-to-face contact with public or are an essential worker, or 3) where case clusters have been identified should be evaluated for possible work-related classification. Describing the occupations and industries of all individuals between the ages of 18-70 who die and are confirmed or probable cases might identify work settings of concern.

Limitations include: It might not be known whether the decedent worked outside the home in the 14 days prior to onset of illness, death certificates list usual occupation and industry and not current occupation and industry at the time of death, the individual maybe retired or disabled at the time of the death, and occupation and industry are typically completed by funeral home staff without direct knowledge of the decedent’s occupational details.